Key result
Rasagiline improves fractional shortening by ~61% vs saline post-MI in rats.
Why the study?
Does rasagiline mesylate attenuate cardiac remodeling in a rat model of experimental myocardial infarction?
Does rasagiline mesylate attenuate cardiac remodeling in a rat model of experimental myocardial infarction?
Rasagiline mesylate attenuates cardiac remodeling, tissue fibrosis, apoptosis, and oxidative stress in a rat model of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for rasagiline post-MI remodeling; leaves open clinical translation.
AIM: Rasagiline mesylate (N-propargyl-1 (R)-aminoindan) (RG) is a selective, potent irreversible inhibitor of monoamine oxidase-B with cardioprotective and anti-apoptotic properties. We investigated whether it could be cardioprotective in a rat model undergoing experimental myocardial infarction (MI) by permanent ligation of the left anterior descending coronary artery. METHODS AND RESULTS: RG was administered, intraperitoneally, for 28 days (2 mg/kg) starting 24 h after MI induction. Echocardiography analysis revealed a significant reduction in left ventricular end-systolic and diastolic dimensions and preserved fractional shortening in RG-treated compared with normal saline group at 28 days post-MI (31.6 ± 2.3 vs. 19.6 ± 1.8, P < 0.0001), respectively. Treatment with RG prevented tissue fibrosis as indicated by interstitial collagen estimation by immunofluorescence staining and hydroxyproline content and attenuated the number of apoptotic myocytes in the border zone (65%) as indicated by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Caspase 3 relative protein levels were significantly decreased in the non-infarcted myocardium. Markedly decreased malondialdehyde levels in the border zone indicate a reduction in tissue oxidative stress. CONCLUSIONS: Our study demonstrates a positive effect of RG in the post-MI period with a significant attenuation in cardiac remodelling.
No takes yet. Share an insight, caveat, or question.
Varela et al. (2017) studied Experimental myocardial infarction. Rasagiline mesylate vs. Normal saline was evaluated on Fractional shortening at 28 days post-MI (p=< 0.0001). Rasagiline mesylate administered for 28 days post-myocardial infarction in rats significantly preserved fractional shortening compared to normal saline (31.6 vs. 19.6, P < 0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: